GSK's Growth Surge Amid U.S. Market Challenges

GSK forecasts robust sales and profit growth, aiming for the upper range of predictions following a strong second-quarter performance. The British pharmaceutical giant is navigating product development challenges and potential tariffs, with ambitions to surpass £40 billion in annual sales by 2031.

CEO Emma Walmsley emphasized GSK's strategic positioning within the expansive U.S. market, which comprises over half of its sales. Engaging in dialogue with former President Donald Trump's administration for potential drug pricing adjustments, GSK continues to target growth despite evolving market conditions.

Driven by advancements in its product pipeline, GSK is expecting five major approvals this year despite looming patent expirations. With significant revenue growth reported in its HIV, specialty medicines, respiratory, and oncology divisions, analysts remain cautious about future sales dynamics.

(With inputs from agencies.)